Syndax Pharmaceuticals agreed on June 3, 2026 to issue $250.0 million of 2.25% convertible notes due 2031 in a private placement, with about $243 million of net proceeds expected. J. Wood Capital Advisors LLC is the sole placement agent, and the company's 2025 net loss was $285.4 million.
Syndax estimates net proceeds of about $243 million from the notes after the placement agent's fees and expenses. The 2.25% notes mature on June 15, 2031, and the conversion price is about $24.76 per share.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $336.5 million, plus short-term investments of $211.4 million, $547.9 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Syndax Pharmaceuticals
Has Syndax Pharmaceuticals raised money recently?
Our latest story on this, dated Jun 4, 2026: "Syndax agrees to $250.0 million private placement of 2.25% convertible notes". The story links the filing or release it is based on. Read the story.
Has Syndax Pharmaceuticals sold convertible notes?
Our latest story on this, dated Jun 4, 2026: "Syndax agrees to $250.0 million private placement of 2.25% convertible notes". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Syndax Pharmaceuticals?
Syndax Pharmaceuticals, Inc. trades under the ticker SNDX on NASDAQ.
Where is Syndax Pharmaceuticals listed?
Syndax Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1T3; LS:A2AFL6; LSX:A2AFL6.
What is the SEC CIK of Syndax Pharmaceuticals?
The SEC Central Index Key (CIK) for Syndax Pharmaceuticals, Inc. is 1395937. Its filings are on SEC EDGAR.
How many shares does Syndax Pharmaceuticals have outstanding?
89,297,086 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Which country or territory is Syndax Pharmaceuticals listed under?
Our directory records Syndax Pharmaceuticals, Inc. under United States.
What does Syndax Pharmaceuticals do?
Our directory classifies Syndax Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Syndax Pharmaceuticals?
The ISIN recorded for Syndax Pharmaceuticals, Inc. is US87164F1057.
Does aibio.space cover Syndax Pharmaceuticals?
aibio.space lists Syndax Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Syndax Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What was Syndax Pharmaceuticals's revenue last year?
$172.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Syndax Pharmaceuticals profitable?
Syndax Pharmaceuticals, Inc. reported a net loss of $285.4 million for the fiscal year ended Dec 31, 2025, and used $323.0 million of cash in operations, per its annual report to the SEC.
How much does Syndax Pharmaceuticals spend on research and development?
$258.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Syndax Pharmaceuticals have?
$547.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Syndax Pharmaceuticals
Members talk about Syndax Pharmaceuticals (SNDX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Syndax Pharmaceuticals, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:SNDX on TradingView.
SEC filings and registration
SEC name
Syndax Pharmaceuticals Inc
CIK
1395937
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
SNDX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
730 THIRD AVENUE, NEW YORK, NY, 10017
Phone
781-419-1400
Shares outstanding
89,297,086 as of 2026-07-31 (10-Q filed 2026-08-04)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Syndax Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SNDX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio